<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Molina, Carlos A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reperfusion Therapy in Acute Stroke: State-of-the-Art and Future Directions</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">Reperfusion therapy with IV rt-PA and recanalization produces good outcomes in patients with acute stroke, but challenges remain. It is estimated that 85% of all ischemic strokes are not treated with thrombolysis; thus, improved and early access to treatment is needed. It is suggested that the 3 to 6-hour time window for treatment may be extended by better patient selection criteria using transcranial Doppler markers of the diffusion-perfusion mismatch method [Restrepo L et al. J Neuroimaging 2006] and combination therapies, such as reduced-dose rt-PA plus eptifibatide [Pancioli AM et al. Stroke 2008] or rt-PA plus GPIIb/IIIa antagonists.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>